Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note released on Thursday. The firm issued a sell rating on the stock.

A number of other research analysts also recently issued reports on SYRS. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Stock Up 20.8 %

Shares of Syros Pharmaceuticals stock opened at $0.09 on Thursday. Syros Pharmaceuticals has a 52-week low of $0.07 and a 52-week high of $6.93. The company has a 50 day moving average of $0.17 and a 200 day moving average of $0.90. The company has a market capitalization of $2.48 million, a P/E ratio of -0.03 and a beta of 1.31.

Hedge Funds Weigh In On Syros Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Exome Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after acquiring an additional 139,400 shares during the period. Two Sigma Securities LLC acquired a new position in shares of Syros Pharmaceuticals in the 4th quarter valued at $25,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Syros Pharmaceuticals in the 3rd quarter valued at $34,000. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.